72 results about "Tanshinone IIA" patented technology

The invention provides application of an enhanced and optimized mesenchymal stem cell exosome in knee osteoarthritis and muscle cartilage injury, and belongs to the technical field of biological medicine. The treatment activity of the umbilical cord mesenchymal stem cell exosome is remarkably improved by combining a composite pretreatment technology with a 3D culture system. Through the synergistic effect of the total flavonoids of rhizoma drynariae and tanshinone IIA, the pathological process of knee osteoarthritis can be regulated and controlled in multiple dimensions, including inflammatory reaction inhibition, cartilage repair promotion and joint function improvement, and the functional limitation of single-component pretreatment is broken through. The invention provides a safe and efficient novel treatment technical strategy for relieving knee osteoarthritis and muscle cartilage injury, and has a wide clinical application prospect.

The invention discloses an application of a salvia miltiorrhiza SmPYL4 gene in regulating and controlling the content of tanshinone. The nucleotide sequence of the salvia miltiorrhiza SmPYL4 gene is as shown in SEQ ID NO. 1. Specifically, the expression of the SmPYL4 gene of the salvia miltiorrhiza is silenced or inhibited, so that the content of tanshinone in hairy roots of the salvia miltiorrhiza is increased. The tanshinone is any one or more than two of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone. The invention further discloses a method for increasing the content of tanshinone in the hairy roots of salvia miltiorrhiza bunge. Researches find that the Salvia miltiorrhiza SmPYL4 gene has a negative regulation effect on synthesis and accumulation of tanshinone components, and the content of the tanshinone components can be effectively increased by silencing the gene. The method has important reference value and significance for cultivation of excellent varieties of salvia miltiorrhiza.

The invention discloses an application of a salvia miltiorrhiza SmPYL8 gene in regulating and controlling the content of tanshinone. The nucleotide sequence of the salvia miltiorrhiza SmPYL8 gene is as shown in SEQ ID NO. 1. Specifically, the expression of the SmPYL8 gene of the Salvia miltiorrhiza is silenced or inhibited, so that the content of tanshinone in hairy roots of the Salvia miltiorrhiza is increased. The tanshinone is any one or more than two of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone. The invention further discloses a method for increasing the content of tanshinone in the hairy roots of salvia miltiorrhiza bunge. Researches find that the Salvia miltiorrhiza SmPYL8 gene has a negative regulation effect on synthesis and accumulation of tanshinone components, and the content of the tanshinone components can be effectively increased by silencing the gene. The method has important reference value and significance for cultivation of excellent varieties of salvia miltiorrhiza.

The invention discloses an application of a salvia miltiorrhiza SmPP2C24 gene in regulating and controlling the content of tanshinone. The nucleotide sequence of the salvia miltiorrhiza SmPP2C24 gene is as shown in SEQ ID NO. 1. Specifically, the expression of the SmPP2C24 gene of the radix salviae miltiorrhizae is silenced or inhibited, so that the content of tanshinone in hairy roots of the radix salviae miltiorrhizae is increased. The tanshinone is any one or more than two of tanshinone I, dihydrotanshinone I, tanshinone IIA and cryptotanshinone. The invention further discloses a method for increasing the content of tanshinone in the hairy roots of salvia miltiorrhiza bunge. Researches find that the Salvia miltiorrhiza SmPP2C24 gene has a negative regulation effect on synthesis and accumulation of tanshinone components, and the content of the tanshinone components can be effectively increased by silencing the gene. The method has important reference value and significance for cultivation of excellent varieties of salvia miltiorrhiza.

The invention discloses a continuous preparation method of sodium tanshinone IIA sulfonate based on a single-tube thin-layer liquid membrane reactor. Comprising the following steps: (1) dissolving tanshinone IIA in an organic solvent as a feed liquid; (2) reacting gas-phase sulfur dioxide with air, and cooling to obtain sulfur trioxide mixed gas; (3) enabling the feed liquid and sulfur trioxide mixed gas to enter a single-tube thin-layer liquid membrane reactor in a parallel flow or reverse flow manner, and carrying out continuous sulfonation reaction to obtain reaction liquid; and (4) adding a sodium salt aqueous solution into the reaction solution to carry out salt forming reaction, centrifuging, drying and purifying to obtain the tanshinone IIA sodium sulfonate. According to the invention, a novel method is adopted to carry out sulfonation reaction on tanshinone IIA, and sulfur trioxide is basically completely consumed after the reaction is finished, so that the generation of waste acid is greatly reduced, and the method has important significance on environmental protection and cost reduction. The green, safe, efficient and continuous preparation of the high-purity tanshinone IIA sodium sulfonate is realized.

The preparation method comprises the following steps: mixing salvia miltiorrhiza-schisandra chinensis superfine powder and roxburgh rose normal juice in a ratio of 3: 2: 5, carrying out composite enzymolysis and saccharomyces cerevisiae pretreatment, and sequentially carrying out aspergillus oryzae solid-state fermentation, acetobacter pasteurianus liquid-state index fed-batch fermentation and lactobacillus plantarum anaerobic flavor fermentation, so as to obtain the vinegar product with the homology of medicine and food. And parameters are regulated and controlled in real time through the three-layer stacked LSTM neural network. According to the invention, the conversion rate of tanshinone IIA to tanshinol reaches 65.8%, the total acid is greater than or equal to 7.2 g / 100mL, at least 21 flavor substances are contained, the batch difference rate is 4.2%, the energy consumption is reduced by 29.2%, the equipment utilization rate is increased by 50%, the product safety reaches the standard, and the method has a health-care function and palatability, and is suitable for industrial production.

The invention discloses a culture method for hypoxia culture of umbilical cord mesenchymal stem cells, which comprises the following steps: hypoxia pre-adaptive culture: inoculating umbilical cord mesenchymal stem cells in a culture medium containing bFGF (basic fibroblast growth factor), glutathione, astragalus polysaccharide and salidroside, and transferring the umbilical cord mesenchymal stem cells into a 5% O2 environment after the umbilical cord mesenchymal stem cells are preliminarily adhered to the wall in a normal oxygen environment; performing low-oxygen enrichment culture: replacing a second culture medium containing astragalus polysaccharide, salidroside, D-ribose, sodium pyruvate and D-glucose, and promoting efficient cell proliferation under 2% O2; performing function strengthening culture: adding tanshinone IIA and GSK-269962A, inducing cells to secrete VEGF under 1% O2, and maintaining high dryness. According to the method, through the synergistic effect of the three-stage gradient oxygen concentration and the specific serum-free culture medium, the cell proliferation multiple is remarkably increased, the total apoptosis rate is reduced, VEGF secretion is promoted, the multidirectional differentiation potential is reserved, the culture method is standardized in operation, the serum-free culture medium is definite in component, and a high-quality stem cell culture scheme is provided for the field of regenerative medicine.

The invention discloses an umbilical cord mesenchymal stem cell serum-free culture medium, which is composed of a basic culture medium and additive components, and the additive components comprise, by final concentration, 5-20 [mu] g / mL of astragalus polysaccharide, 0.5-2.0 [mu] g / mL of salidroside, 0.1-0.5 [mu] g / mL of tanshinone IIA, 0.1-0.3 mg / mL of sodium pyruvate, 5-15 mM of D-ribose, 3-6 mg / mL of recombinant human albumin, and 5-10 [mu] g / mL of recombinant transferrin; the invention also discloses a method for culturing umbilical cord mesenchymal stem cells under the hypoxia condition by using the serum-free culture medium. The method comprises the steps of cell inoculation, culture under the hypoxia condition, subculture, cell passage and the like. The astragalus polysaccharide, the salidroside, the tanshinone IIA, the sodium pyruvate, the recombinant human albumin and the recombinant transferrin are added into the serum-free culture medium, so that nutrition supply and function maintenance of cells under a low-oxygen condition are guaranteed, the proliferation rate and the differentiation capacity of the cultured cells are improved, the apoptosis rate of the cells is reduced, and the survival rate of the cells is increased. Wide application prospects are realized in the fields of cell culture, regenerative medicine and the like.

The present application relates to the technical field of medicine, in particular to the application of gansix triol A in the preparation of a drug for treating gastric cancer and / or non-small cell lung cancer, gansix triol A plays an anti-gastric cancer role by selectively inhibiting the proliferation of gastric cancer MGC-803 cells and inhibiting angiogenesis, the mechanism involves inhibiting the VEGF / VEGFR2 signal pathway and inducing cell apoptosis; the mechanism of gansix triol A in inhibiting the VEGF / VEGFR2 signal pathway is similar to that of bevacizumab; gansix triol A plays an anti-non-small cell lung cancer role by selectively inhibiting the proliferation of non-small cell lung cancer A549 cells, the mechanism involves inhibiting the MAPK / ERK signal pathway and inducing cell apoptosis. The present application finds that the cytotoxic activity of gansix triol A on MGC-803 cells and A549 cells is significantly stronger than that of tanshinone IIA; gansix triol A has an anti-tumor effect of "one drug with double targets, double inhibition" and "high efficiency and low toxicity".

The invention belongs to the technical field of high polymer materials, and particularly relates to multifunctional hydrogel co-loaded with radix astragali-radix salviae miltiorrhizae components and a preparation method of the multifunctional hydrogel. The preparation method comprises the following steps: dissolving methacrylated silk fibroin and methacrylated astragalus polysaccharide in water containing a photoinitiator to obtain an SFMA-APMA hydrogel solution, then adding tanshinone IIA-loaded nano-micelles, uniformly mixing to obtain an SFMA-APMA-TSIIA-coated HA-PPS hydrogel solution, and irradiating the SFMA-APMA-TSIIA-coated HA-PPS hydrogel solution under ultraviolet light for 2-4 minutes to obtain the multifunctional hydrogel co-loaded with astragalus-salvia miltiorrhiza components. The preparation method comprises the following steps: grafting polypropylene sulfide and hyaluronic acid to form an amphiphilic nano-micelle, loading tanshinone IIA into an inner core of the micelle by utilizing a hydrophobic effect, and loading the nano-micelle into double-network hydrogel formed by cross-linking methylacryloylated astragalus polysaccharide and methylacryloylated silk fibroin. Local medicine storage and targeted slow release of the active ingredients of the traditional Chinese medicine can be realized.

The invention discloses a traditional Chinese medicine combination effective part capable of improving diabetic peripheral neuropathy. The traditional Chinese medicine combination effective part is prepared from a volatile oil effective part, a water-soluble effective part and an alcohol-soluble effective part, the effective part of the volatile oil comprises alpha-ocimene, alpha-santalene, bisabolol, beta-bisabolol and nerolidol; the water-soluble effective part comprises salvianolic acid A, salvianolic acid B and tanshinol; the alcohol-soluble effective part is prepared from Z-ligustilide, alpha-masticinic acid, beta-masticinic acid, tanshinone IIA, and 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone, and the alcohol-soluble effective part is prepared from the following raw materials in parts by weight: 2-methoxy-5-acetyl-furangermacane-1 (10)-ene-6-ketone. The traditional Chinese medicine composition effective part provided by the invention can regulate blood sugar, improve the conduction speed of sciatic nerves, repair damaged tissues, inhibit oxidative stress reaction, resist inflammation and relieve pain, so that the diabetic peripheral neuropathy is improved, the curative effect is reliable, the safety is good, the adverse reaction is low, and the traditional Chinese medicine composition effective part can be used for preparing a medicinal preparation for improving the diabetic peripheral neuropathy.

The invention discloses a preparation method and application of tanshinone IIA and cryptotanshinone amide derivatives. The tanshinone IIA and cryptotanshinone amide derivatives are compounds shown in a general formula (I) or stereoisomers, racemes, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, pharmaceutically acceptable salts or prodrugs of the compounds. The tanshinone IIA and cryptotanshinone amide derivative can be used for preparing anti-inflammatory drugs, antibacterial drugs, tumor drugs, drugs for treating cardiovascular and cerebrovascular diseases, drugs for treating burns and scalds and drugs for treating infectious diseases.

This invention discloses a Zhishu Yangwei tablet for chronic gastritis and its granule dry-compression tableting process, relating to the field of traditional Chinese medicine preparation technology. The Yangwei tablet is made from the following raw materials in parts by weight: Codonopsis pilosula 35-45 parts, stir-fried Atractylodes macrocephala 18-22 parts, Poria cocos 18-22 parts, Glycyrrhiza uralensis 8-12 parts, Amomum villosum 18-22 parts, Lindera strychnifolia 18-22 parts, Salvia miltiorrhiza 45-55 parts, roasted Aucklandia lappa 18-22 parts, Paeonia lactiflora 18-22 parts, stir-fried Citrus aurantium 18-22 parts, Magnolia officinalis 28-32 parts, Lilium brownii 35-45 parts, and stir-fried chicken gizzard lining 18- 22 parts, dried plum 45-55 parts, Coptis chinensis 8-12 parts, hawthorn 35-45 parts, magnesium stearate 5-7 parts, sucrose 28-32 parts; This invention uses low-temperature dynamic extraction technology to replace the traditional high-temperature decoction process, effectively reducing the decomposition loss of heat-sensitive active ingredients such as tanshinone IIA and ursolic acid, and improving the bioavailability of the drug. It also uses membrane concentration and spray drying technology to replace the traditional atmospheric pressure concentration and oven drying process, shortening the production cycle, reducing energy consumption, and avoiding the degradation of active ingredients caused by prolonged heating of materials.

The present invention discloses a method for screening effective substances of traditional Chinese medicine based on a 6-dimensional spider web model, belonging to the field of medical technology. Based on the results of UHPLC analysis, the present invention uses danshensu, chlorogenic acid, procyanidin B2, epicatechin, hyperoside, isoquercetin, rosmarinic acid, lithospermic acid, salvianolic acid B, salvianolic acid A, dihydrotanshinone I, tanshinone I, cryptotanshinone, tanshinone IIA, oleanolic acid, and ursolic acid as the "specific" candidate effective ingredients of the Danshen-Hawthorn medicinal pair. Based on the data of the candidate effective ingredients in six dimensions, namely, effectiveness dimension, compatibility environment dimension, transmission and traceability dimension, content measurability dimension, network pharmacology degree value dimension, and molecular docking target binding activity dimension, a "spider web" model is constructed to obtain the key effective substances of the Danshen-Hawthorn medicinal pair. The present invention provides theoretical support for revealing the compatibility theory of the Danshen-Hawthorn medicinal pair, formulating its quality evaluation standards, and clinical application of the Danshen-Hawthorn medicinal pair.

This invention discloses a traditional Chinese medicine composition and its preparation method for treating liver, kidney, and cardiovascular diseases, relating to the field of traditional Chinese medicine preparations. It is made from the following raw materials in parts by weight: 10-30 parts of Gastrodia elata, 15-40 parts of Salvia miltiorrhiza, 10-25 parts of Panax quinquefolius, 10-30 parts of Panax notoginseng, 5-20 parts of Chrysanthemum morifolium, and 10-15 parts of Gecko. This traditional Chinese medicine composition and its preparation method for treating liver, kidney, and cardiovascular diseases features synergistic innovation in formulation, is suitable for specific populations, and achieves the therapeutic effects of clearing liver heat, promoting blood circulation, nourishing qi and yin, and tonifying the liver and kidneys. The process preserves the active ingredients, is suitable for absorption by middle-aged and elderly individuals, and maximizes the retention of heat-sensitive active ingredients such as gastrodin, total saponins of Panax notoginseng, tanshinone IIA, and total flavonoids of Chrysanthemum morifolium. The dosage form is flexible and adaptable, with a wide range of applications. Both the ultrafine powder and oral liquid preparations avoid irritating components. The application is clearly targeted, with significant differentiated advantages, especially suitable for middle-aged and elderly men around 70 years old and individuals with hyperglycemia and dizziness.

This invention discloses a method for inducing pluripotent stem cells to differentiate into skin keratinocytes and its culture medium, solving problems such as long differentiation cycles, low yields, insufficient purity, and animal-derived contamination in existing technologies. The first stage uses medium I containing FGF2 and tanshinone IIA to promote mesodermal differentiation. The second stage uses medium II containing BMP4, EGF, dexamethasone, and PVA to regulate and synergistically induce the BMP / ERK signaling pathway. The final stage uses medium III for expansion culture, obtaining fibroblasts with a purity >99% within 20 days. This method is non-invasive, simple, and low-cost, with potential for large-scale production. The obtained cells can be used for skin regeneration, disease modeling, drug screening, and clinical treatment, demonstrating significant medical application and industrial transformation value.

The invention discloses a salvia miltiorrhiza endogenous oligopeptide composition and application thereof. The composition contains salvia miltiorrhiza endogenous oligopeptides miPEP167b-5p and miPEP171b-1, wherein the concentration ratio of the salvia miltiorrhiza endogenous oligopeptides miPEP167b-5p to the miPEP171b-1 is 0.8-1.2. The oligopeptide used in the composition has high species specificity, does not promote the growth of other plants in the field, and avoids the ecological risk of a traditional broad-spectrum growth regulator. Field experiment results show that after the composition is applied to treatment, the root system yield of salvia miltiorrhiza is increased by 56% compared with that of a control group, the number of roots is increased by 435% compared with that of the control group, the rosmarinic acid content is increased by 43% compared with that of the control group, the salvianolic acid B content is increased by 81%, the tanshinone I content is increased by 214%, the tanshinone IIA content is increased by 75%, the leap-type improvement of the salvia miltiorrhiza medicinal material yield and quality is synchronously achieved, and the application prospect is wide. And reliable technical support is provided for green, efficient and high-quality development of the salvia miltiorrhiza industry.

The invention discloses screening of transcriptome biomarkers responsive to tanshinone IIA and application of the transcriptome biomarkers in sepsis diagnosis and treatment kits. Tanshinone IIA (TSA) inhibits an SAMSN1 gene in a targeted manner by up-regulating expression of mmu-miR-1896, so that an NRF2 / KEAP1 antioxidant pathway is activated, and GSDMD-mediated pyroptosis is inhibited, thereby reducing multi-organ injury. 10-20 mg / kg of TSA can significantly improve the alveolar structure of the LPS model and reduce inflammatory factors. A kit which is developed on the basis of the mechanism and is used for detecting the expression levels of mmu-miR-1896, SAMSN1 and NRF2-Kea1-GSDMD can be used for evaluating the curative effect.

The invention belongs to the field of traditional Chinese medicine compounds, and particularly relates to a method for simultaneously extracting tanshinone IIA and salvianolic acid B from salvia miltiorrhiza. According to the specific technical scheme, the preparation method comprises the following steps: putting salvia miltiorrhiza powder into a container, adding an ethyl lactate solution, mixing, oscillating and shaking uniformly, then carrying out ultrasonic treatment and centrifugation, and taking supernate, so as to obtain a mixed solution of tanshinone IIA and salvianolic acid B; according to the ultrasonic-assisted green solvent ethyl lactate extraction method obtained through optimization, tanshinone IIA and salvianolic acid B with large polarity difference in salvia miltiorrhiza can be extracted at the same time. The extraction method disclosed by the invention is simple in operation steps, and the yield of active ingredients and the utilization rate of raw materials are relatively ideal. The method has the advantages of being simple in process, safe, low in cost, environmentally friendly, convenient to operate, good in reproducibility, short in period, capable of avoiding degradation of effective components and the like.

The invention relates to the technical field of scar repair medicines, in particular to compound scar traditional Chinese medicine microemulsion gel which is composed of traditional Chinese medicine functional components, microemulsion components, gel matrix components and auxiliary materials. The traditional Chinese medicine functional components comprise tanshinone IIA, asiaticoside, an angelica sinensis extract, dipotassium glycyrrhizinate and ligustrazine; the microemulsion component comprises an oil phase, an emulsifier, a co-emulsifier and a water phase, the emulsifier is a compound of polyoxyethylene hydrogenated castor oil EL-40 and Tween 80, and the co-emulsifier comprises 1, 2-propylene glycol; the gel matrix component is prepared from carbomer 940, hydroxypropyl methyl cellulose, triethanolamine and purified water; the auxiliary materials comprise phenoxyethanol and sodium hyaluronate. According to the invention, a scientific traditional Chinese medicine compound system is constructed, and a plurality of functional components have a synergistic effect and respectively play the roles of resisting inflammation, inhibiting fibroblast proliferation, promoting tissue repair, improving local blood circulation and the like.

The present invention discloses a tanshinone benzimidazole fluorescent probe, a preparation method thereof, and an application thereof in detecting BF3. Tanshinone IIa is directly subjected to a condensation reaction with 2-hydroxy-5-methylbenzaldehyde and ammonium acetate to prepare 4-methyl-2-(1,6,6-trimethyl-7,8,9,12-tetrahydro-6H-furo[2',3':1,2]phenanthren[3,4-d]imidazol-11-yl)phenol. The compound can selectively react with BF3. After the reaction, green fluorescence is weakened and blue fluorescence is enhanced. The compound can be used as a fluorescent probe for detecting BF3.

This invention discloses a brain-targeting neutrophil membrane-encapsulated tanshinone IIa PLGA nanoparticle formulation, its preparation method, and its uses. The brain-targeting tanshinone IIa nanoparticle formulation, Neu-Tan-IIa@PLGA, is characterized by comprising a PLGA-loaded tanshinone IIa nanoparticle core (Tan-IIa@PLGA) and an outer neutrophil membrane coating. This invention effectively overcomes the problems of poor water solubility, low oral bioavailability, and difficulty in crossing the blood-brain barrier associated with tanshinone IIa. This invention provides a tanshinone IIa with strong targeting and high drug stability, enabling delivery to lesions in ischemic brain regions and improving the safety and efficacy of stroke treatment.

The invention discloses a method for detecting effective components of a radix salviae miltiorrhizae extracting solution based on a Raman spectrum and a neural network, and belongs to the field of analysis and detection. The detection method comprises the following steps: providing a salvia miltiorrhiza extracting solution sample; acquiring Raman spectrum characteristic data of the extracting solution sample; and inputting the Raman spectrum characteristic data into a quantitative detection model of the effective components of the salvia miltiorrhiza, and determining the concentrations of tanshinone I, tanshinone IIA and salvianolic acid B in the sample to be detected. The method has the advantages of being high in prediction precision (the correlation coefficient R2 reaches 0.98), high in universality and free of destructiveness, and is suitable for rapid quality evaluation of the traditional Chinese medicine compound preparation.

The application discloses a tanshinone MAPK4 protein kinase and application of a coding gene thereof in regulating tanshinone content in Salvia miltiorrhiza. The application finds that the tanshinone MAPK4 protein kinase can improve gene transcription level and protein level of a key synthesis enzyme on a tanshinone synthesis path, and then improves tanshinone content (such as tanshinone IIA, dihydrotanshinone I, cryptotanshinone and tanshinone I) in Salvia miltiorrhiza. Therefore, the tanshinone MAPK4 protein kinase, the coding gene and an expression vector containing the coding gene can be used for regulating and improving tanshinone in Salvia miltiorrhiza.

The invention provides a multi-index quality control method of a tanshinone-trimetazidine Chinese and western medicine compound medicament, which comprises the following steps of: selecting indexes: determining three types of core detection indexes, including characteristic components: tanshinone IIA (a representative component of tanshinone) and trimetazidine (a western medicine active component); safety indexes are related substances (such as tanshinone degradation products and trimetazidine oxidation products); the homogeneity index is content homogeneity (component content deviation in a single dose unit); the detection method comprises the following steps: simultaneously determining characteristic components and related substances by adopting a high performance liquid chromatography (HPLC) method, and pre-treating a sample: taking 0.5 g of compound medicament powder, adding 50mL of methanol, carrying out ultrasonic extraction for 30 minutes (the power is 300W and the frequency is 40kHz), filtering, and taking a subsequent filtrate as a test solution. Multi-index cooperative control: characteristic components, related substances and content uniformity are detected at the same time, the quality of the compound medicament is comprehensively reflected, and the limitation of a single index is avoided.

The invention discloses a salvia miltiorrhiza quality evaluation method based on HPLC-DAD and multivariate analysis, and relates to the technical field of medicine quality evaluation, and the salvia miltiorrhiza quality evaluation method comprises the following steps: extracting effective components from salvia miltiorrhiza medicinal material samples collected from different regions by adopting an extraction solvent, the effective components at least comprise salvianic acid A sodium, rosmarinic acid, salvianolic acid B, cryptotanshinone, tanshinone I and tanshinone IIA, HPLC-DAD is adopted for chromatographic analysis, and the extracted effective components are subjected to multivariate statistical analysis. According to the system, the quality difference of salvia miltiorrhiza from different producing areas is evaluated, and scientific basis and data support are provided for standardized planting, producing area screening and clinical reasonable application of salvia miltiorrhiza medicinal materials.

The invention discloses a tanshinone IIA derivative as well as a preparation method and application thereof, and provides a set of systematic chemical synthesis route for overcoming the defects that tanshinone IIA is poor in water solubility and low in bioavailability and the antitumor activity needs to be improved. A series of novel derivatives with various structures and general formula structures and pharmaceutical salts thereof are prepared. The core of the technical scheme is that after a specific functional group is introduced into the derivative, the water solubility and the stability of the compound are remarkably improved, and the derivative particularly shows excellent anti-colorectal cancer activity, can effectively inhibit tumor cell proliferation and tumor growth in an animal model, and does not have obvious toxic or side effects. The invention also provides a pharmaceutical composition containing the derivative and application of the pharmaceutical composition in preparation of medicines for preventing, relieving or treating colorectal cancer, and provides an important candidate compound for developing a high-efficiency and low-toxicity novel anti-colorectal cancer medicine.

The present invention discloses a long-branch Trichoderma strain and a freeze-dried powder thereof for enhancing the fat-soluble medicinal components of Salvia miltiorrhiza, and belongs to the field of microbial technology. The strain is named SBa-TL, and is deposited in the China Center for Type Culture Collection on April 18, 2025, with a deposit number of CCTCC NO: M 2025821. The present invention provides a long-branch Trichoderma strain and a long-branch Trichoderma freeze-dried powder that can enhance the fat-soluble medicinal components of Salvia miltiorrhiza. The strain and the freeze-dried powder prepared therefrom can effectively promote the growth of Salvia miltiorrhiza plants, increase the above-ground and underground biomass of Salvia miltiorrhiza plants, and significantly improve the content of medicinal components in Salvia miltiorrhiza, especially increase the content of tanshinone I, tanshinone IIA and cryptotanshinone. In the cultivation of improving the quality of Salvia miltiorrhiza, the strain has significant application value.

The invention discloses tanshinone derivatives with antithrombotic activity as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The tanshinone derivative is obtained by structurally modifying tanshinone IIA and cryptotanshinone, the polarity and pharmacological activity are remarkably improved, the bioavailability is greatly improved, the problem that the tanshinone IIA and the cryptotanshinone are limited in clinical application is solved, and the problems that the tanshinone IIA and the cryptotanshinone are high in lipid solubility, difficult to prepare into proper dosage forms, affected in absorption and distribution of drugs, short in half-life period, required to be frequently administered and poor in bioavailability are solved. And inconvenience is brought to the patient. Part of tanshinone derivatives have remarkable anticoagulant activity; the synthetic method is simple to operate and controllable in condition, a series of derivatives can be efficiently synthesized, and the derivatives have the biological activities of anticoagulation, platelet aggregation resistance, thrombosis resistance and the like, are the key for the antithrombotic drugs to play a therapeutic role, provide efficient and safe candidate drugs for cardiovascular and cerebrovascular diseases, and have remarkable technical advantages and huge market potential.

This application relates to a method for cultivating high-yield cannabinoid and tanshinone adventitious roots of industrial hemp, belonging to the field of adventitious root cultivation technology. The method includes inducing industrial hemp adventitious roots with yeast extract to obtain induced adventitious roots. Yeast extract is low-cost and readily available, and as an inducer, it can stimulate industrial hemp adventitious roots to synthesize more target metabolites. The induced adventitious roots are then scaled up and cultured in a bioreactor, promoting cell proliferation and growth, and increasing the biomass of the adventitious roots. Simultaneously, it promotes the accumulation of more target metabolites in the adventitious roots, with yields of cannabinoids, cannabidiol, tetrahydrotanshinone I, tanshinone IIA, and dihydrotanshinone I reaching as high as 80.65, 53.58, 103.76, 21.71, and 5.71 mg / L DW, respectively. This method saves on operational steps and labor intensity, and overcomes the shortcomings of low biomass and low cannabinoid yield in existing industrial hemp adventitious root culture technology. It can achieve year-round economical and efficient cultivation of industrial hemp adventitious roots with high yields of cannabinoids and tanshinone.